Anti-MCSP [LHM 2]

Anti-MCSP (LHM2) antibody is a very good marker for melanoma (>90% stained).

Contributors

Inventor Institute
Nick Tidman Queen Mary University of London
Cat. #: 151118
Tool sub type: Primary antibody
Unit size: 100 ug
Research Fields: Cell biology;Cancer;Neurobiology
Application: IHC ; FACS ; IHC ; IF ; IP ; WB ; ICC
Target: Melanoma associated Chondroitin Sulphate Proteoglycan (MCSP or NG2)
Reactivity: Human
Clone: LHM 2
Host: Mouse
Class: Monoclonal
Product description: Monoclonal antibody against MCSP melanoma marker.
Conjugation: Unconjugated
Isotype: IgG1 kappa
Molecular weight: 240 kDa
Immunogen: A 375P cells crude extract.
Immunogen Uniprot ID: Q6UVK1
Myeloma used: NS0
Target background: MCSP is a chondroitin surface proteoglycan, involved in stabilizing cell-substratum interactions during early events of cell spreading. MCSP is an integral membrane chondroitin sulphate proteoglycan expressed by human malignant melanoma cells. Anti-MCSP (LHM2) antibody is a very good marker for melanoma (>90% stained). LHM2 also stains basal cell carcinomas and subpopulation of basal keratinocytes. LHM2 can be used as a diagnostic panel for immunopathology of malignant melanoma and potential candidates for immunoimaging and immunotherapy of disseminated melanoma. Potential applications of the LHM2 antibody include use for separation/isolation of epidermal stem cells, detection of stem cells in skin biopsies or epithelial cell cultures and optimisation of culture conditions to retain epidermal stem cell population in in vitro cultures.
Format: Liquid
Concentration: 1 mg/ml
Storage buffer: PBS with 0.02% azide
Storage conditions: Store at -20° C frozen. Avoid repeated freeze / thaw cycles
Shipping conditions: Dry ice
References:

Li et al. 2019. Theranostics. 9(17):5105-5121. PMID: 31410204.

Arrigoni et al. 2016. Adv Healthc Mater. 5(13):1617-26. PMID: 27191352.

Loibl et al. 2014. Biomed Res Int. 2014:395781. PMID: 24563864.

Somaiah et al. 2012. Clin Cancer Res. 18(19):5479-88. PMID: 22855580.

Somaiah et al. 2012. Clin Cancer Res. 18(19):5479-88. PMID: 22855580.

The relationship between homologous recombination repair and the sensitivity of human epidermis to the size of daily doses over a 5-week course of breast radiotherapy.

Kinney et al. 2012. Ann Neurol. 71(3):397-406. PMID: 22451205.

Pierce et al. 2011. Aging Cell. 10(6):1032-7. PMID: 21943306.

Ghali et al. 2004. J Invest Dermatol. 122(2):433-42. PMID: 15009727.

Epidermal and hair follicle progenitor cells express melanoma-associated chondroitin sulfate proteoglycan core protein.

Kupsch et al. 1999. Clin Cancer Res. 5(4):925-31. PMID: 10213230.

Isolation of human tumor-specific antibodies by selection of an antibody phage library on melanoma cells.

Kupsch et al. 1995. Melanoma Res. 5(6):403-11. PMID: 8589614.

Generation and selection of monoclonal antibodies, single-chain Fv and antibody fusion phage specific for human melanoma-associated antigens.

Images

View Gallery
Coexpression of pericyte markers on MSCs after direct coculture with EPCs for 7 days in IMDM-FCS (top row) or IMDM-PL (bottom row). Immunofluorescence staining for CD146; NG2; and ?SMA demonstrated double positive cells for each combination (CD146 and NG2; CD146 and ?SMA; and NG2 and ?SMA). Negative controls were stained only with the fluorescent labelled secondary antibody. Cell nuclei are stained with DAPI (blue). Scale bars = 50??m. Adapted from Loibl M et al. Direct cell-cell contact between mesenchymal stem cells and endothelial progenitor cells induces a pericyte-like phenotype in vitro. Biomed Res Int 2014

Related Tools for Antibodies

Cat. # Tool Name
151019 Anti-Mos [S3.1] Key Info View Tool
151021 Anti-CyclinB1 [V152] Key Info View Tool
151022 Anti-IL12 [1-1A4] Key Info View Tool
151036 Anti-ICAM1 [15.2] Key Info View Tool
151038 Anti-Cytochrome P450 4A2, 4A3 [Clo4] Key Info View Tool

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.